Results 271 to 280 of about 18,913,418 (345)

Precision Antisense Oligonucleotide Therapy Amenability for Infantile Genetic Epilepsies.

JAMA Neurol
Sherrill E, Cheerie D, Beck CJ, Whittle EF, Shafi Y, Chandler NJ, Christodoulou J, Daniel J, Hassell J, Lachgar-Ruiz M, Mulhern S, Scotchman E, Sidhu J, Tedja CF, Chitty LS, Cross JH, Scheffer IE, Zhou H, Yu TW, Chau V, Stephenson SEM, Poduri A, Howell KB, McTague A, Costain G, D'Gama AM, Gene-STEPS Study Group.   +26 more
europepmc   +1 more source

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Journal of the American College of Cardiology, 2021
BACKGROUND REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) randomized statin-treated patients with elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in adjudicated events,
Philippe Gabriel Steg, Lixia Jiao
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Journal of the American Academy of Dermatology, 2020
BACKGROUND An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization.
Kristian Reich, Amy S. Paller
exaly   +2 more sources

First dose‐ranging study of remimazolam in Japanese patients undergoing gastrointestinal endoscopy: Phase II investigator‐initiated clinical trial

Digestive Endoscopy, 2022
Remimazolam, an ultra‐short‐acting benzodiazepine, has been used for procedural sedation in the United States. We conducted an investigator‐initiated clinical trial to determine the appropriate dose of remimazolam required for sedation during ...
Ryoji Ichijima, Hisatomo Ikehara, T. Maeda, Tomomi Sugita, T. Horii, Aya Iwao, K. Ogura, Chika Kusano, Y. Kondo, Takahiro Suzuki, T. Gotoda   +10 more
semanticscholar   +1 more source

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.

The Lancet Oncology, 2020
BACKGROUND TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer. Inspired by the encouraging results of a small phase 1-2 study, C-TASK FORCE,
P. Pfeiffer, M. Yilmaz, Sören Möller, D. Zitnjak, M. Krogh, L. Petersen, L. Poulsen, S. Winther, K. G. Thomsen, C. Qvortrup   +9 more
semanticscholar   +1 more source

Cyber Crime Investigator's Field Guide

, 2022
From the Publisher: Long gone are the days when a computer took up an entire room. Now we have computers at home, laptops that travel just about anywhere, and data networks that allow us to transmit information from virtually any location in a timely ...
B. Middleton
semanticscholar   +1 more source

Investigating Investigators: Examining Witnesses' Influence on Investigators.

Law and Human Behavior, 2006
This research examined the influence of eyewitness identification decisions on participants in the role of police investigators. Undergraduate "investigators" interviewed confederate "witnesses" and then searched a computer database of potential suspects.
Leora C. Dahl, D. Stephen Lindsay, C. A. Elizabeth Brimacombe   +2 more
openaire   +2 more sources

Developmental validation of QIAGEN Investigator® 24plex QS Kit and Investigator® 24plex GO! Kit: Two 6-dye multiplex assays for the extended CODIS core loci

Forensic Science International: Genetics, 2017
The original CODIS database based on 13 core STR loci has been overwhelmingly successful for matching suspects with evidence. In order to increase the power of discrimination, reduce the possibility of adventitious matches, and expand global data sharing,
M. Kraemer, Anke Prochnow, M. Bussmann, M. Scherer, R. Peist, C. R. Steffen   +5 more
exaly   +2 more sources